Hubbry Logo
OptochinOptochinMain
Open search
Optochin
Community hub
Optochin
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Optochin
Optochin
Optochin
View on Wikipedia
from Wikipedia
Optochin
Names
IUPAC name
(4β,8α,9R)-6'-Ethoxy-10,11-dihydrocinchonan-9-ol
Other names
Ethylhydrocupreine
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard 100.007.577 Edit this at Wikidata
MeSH Optochin
UNII
  • InChI=1S/C21H28N2O2/c1-3-14-13-23-10-8-15(14)11-20(23)21(24)17-7-9-22-19-6-5-16(25-4-2)12-18(17)19/h5-7,9,12,14-15,20-21,24H,3-4,8,10-11,13H2,1-2H3/t14-,15-,20-,21+/m0/s1 ☒N
    Key: SUWZHLCNFQWNPE-LATRNWQMSA-N ☒N
  • InChI=1/C21H28N2O2/c1-3-14-13-23-10-8-15(14)11-20(23)21(24)17-7-9-22-19-6-5-16(25-4-2)12-18(17)19/h5-7,9,12,14-15,20-21,24H,3-4,8,10-11,13H2,1-2H3/t14-,15-,20-,21+/m0/s1
    Key: SUWZHLCNFQWNPE-LATRNWQMBV
  • CC[C@H]1CN2CC[C@H]1C[C@H]2[C@@H](c3ccnc4c3cc(cc4)OCC)O
Properties
C21H28N2O2
Molar mass 340.46 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Optochin (or ethylhydrocupreine hydrochloride) is a derivative of quinine introduced in 1911 by Morgenroth and Levy with the intention to treat pneumococci infection.[1] In very high dilutions, it inhibits the growth of representatives of all four groups of pneumococci in vitro. That is the main reason it is now used in bacteriology for the differentiation of Streptococcus pneumoniae, which is optochin-sensitive, from the other, resistant alpha-hemolytic streptococci, sometimes called the viridans streptococci because of the green colouration on blood agar around colonies.

The growth of bacteria that are optochin-sensitive will show a zone of inhibition around an optochin disc, while the growth of bacteria that are resistant to optochin will not be affected. In vitro, a minimum inhibitory concentration (MIC) of 1:10,000,000 will inhibit the growth of pneumococci, and 1:500,000 is bactericidal.[2]

Resistance

[edit]

For decades, Streptococcus pneumoniae has been considered susceptible to optochin; but some strains have been found to be resistant to optochin in laboratory testing. This is notable because the emergence of optochin-resistant strains would invalidate the distinguishing test described above.[3]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Optochin

View on Grokipedia
from Grokipedia
Optochin, chemically known as ethylhydrocupreine with the molecular C₂₁H₂₈N₂O₂, is a semisynthetic derivative of the . Developed in 1911 by Paul Morgenroth and Julius Levy as an antibacterial agent, it was initially used to treat infections caused by , including and septicemia, though its clinical application was limited by and the emergence of resistance. Today, optochin primarily serves as a diagnostic in clinical laboratories for the presumptive identification of S. pneumoniae among alpha-hemolytic streptococci, exploiting the bacterium's characteristic sensitivity to the compound. The optochin susceptibility test, a standard phenotypic assay, involves inoculating a bacterial isolate onto a blood agar plate (typically tryptic soy agar with 5% sheep blood) and applying a 6-mm disc impregnated with 5–6 μg of optochin; S. pneumoniae isolates produce a zone of inhibition ≥14 mm in diameter when incubated in 5% CO₂ at 35–37°C, distinguishing them from optochin-resistant species like Streptococcus mitis or S. oralis. This sensitivity arises from optochin's inhibition of the bacterial F₀F₁-ATPase enzyme complex, which disrupts ATP synthesis and cellular energy production in susceptible strains. While effective for routine identification, the test's reliability can be affected by factors such as media type, incubation atmosphere, and the presence of optochin-resistant S. pneumoniae variants, which occur at low frequencies (0.5–2%) globally. Optochin resistance in S. pneumoniae typically results from point mutations in the atpC or atpA genes encoding subunits of the , altering the enzyme's structure to evade inhibition; for instance, mutations like Trp206Cys in atpA have been documented in clinical isolates from regions including . Despite its historical role as one of the earliest synthetic —predating sulfa drugs and penicillin—optochin's therapeutic use ended by the mid-20th century due to superior alternatives, but its diagnostic value persists, often complemented by solubility tests or molecular methods like PCR for capsule genes to confirm S. pneumoniae identity. Recent research has explored optochin derivatives as scaffolds for novel, narrow-spectrum inhibitors targeting pneumococcal , aiming to address resistance challenges.

Background

Introduction

Optochin, chemically known as ethylhydrocupreine , is a synthetic of with selective properties targeted against pneumococci. Its molecular formula is C21_{21}H29_{29}ClN2_{2}O2_{2}. In modern clinical , optochin serves primarily as a diagnostic for identifying , the causative agent of pneumococcal infections, by differentiating it from other alpha-hemolytic streptococci. This susceptibility test exploits optochin's inhibitory effect on pneumococcal growth, enabling presumptive identification in laboratory settings. The compound's specificity arises from its quinine-based structure, which disrupts bacterial processes in susceptible strains, though its therapeutic use has largely been supplanted by safer antibiotics.

History

Optochin, chemically known as ethylhydrocupreine hydrochloride, was first synthesized in 1911 by Julius Morgenroth and Richard Levy, two German researchers working at the , as a derivative specifically designed to combat pneumococcal infections caused by . Their work stemmed from efforts to develop targeted chemotherapeutics against bacterial pathogens, building on quinine's antimalarial properties to create a compound with enhanced bactericidal activity against pneumococci. In a foundational publication, they detailed its pneumocidal effects in experimental models, marking optochin as one of the earliest synthetic antimicrobials aimed at systemic infection treatment. Early clinical trials in the 1910s explored optochin's potential for treating acute , a leading cause of mortality at the time, with studies such as those conducted by Moore and colleagues in 1917–1918 administering the drug intravenously to patients. However, these trials revealed limited therapeutic efficacy, as the agent failed to consistently resolve infections despite initial promising results. Key limitations included severe toxicity, notably irreversible damage to the and vision impairment, alongside rapid emergence of resistance; resistance was already documented in pneumococci from infected mice treated with optochin precursors as early as 1910, and clinical isolates showed similar patterns by 1912. Due to these shortcomings, optochin was largely abandoned as a therapeutic by the , pivoting instead to applications for distinguishing pneumococci from other alpha-hemolytic streptococci in laboratory settings. This repurposing aligned with the era's therapeutic landscape, where serum therapies dominated pneumococcal treatment until the introduction of sulfonamides in the mid-1930s and penicillin in the , which offered safer and more effective alternatives. The diagnostic utility of optochin's selective inhibition of pneumococcal growth had been observed as early as in studies noting its broth culture effects, facilitating its adoption in microbiological differentiation. Following , optochin testing gained standardization in the 1950s as a routine disk diffusion assay, with Bowers and Jeffries advocating its use in clinical for presumptive pneumococcal identification through zone-of-inhibition measurements on blood agar plates. This method was incorporated into laboratory manuals and protocols, solidifying optochin's role as a key diagnostic amid expanding options.

Diagnostic Applications

Bacterial Identification

Optochin serves as a key tool in the presumptive identification of within clinical workflows, where it differentiates this pathogen from morphologically similar alpha-hemolytic streptococci. In the test, S. pneumoniae isolates produce a distinct zone of inhibition (typically ≥14 mm) around an optochin-impregnated disk placed on blood agar, whereas viridans group streptococci remain unaffected and show no such zone. This identification method is routinely applied to primary cultures from clinical samples in cases of suspected pneumococcal disease, including , , and bacteremia, with specimens commonly derived from , (CSF), or . To achieve confirmatory , optochin results are frequently paired with complementary assays such as the bile solubility test, which demonstrates S. pneumoniae's unique ability to lyse in the presence of bile salts, or the , which visualizes the using specific antisera. The optochin test offers significant advantages as a rapid and cost-effective preliminary screen, particularly in resource-limited settings, with reported sensitivity up to 99% and specificity of 98% for distinguishing S. pneumoniae from . Despite its utility, the test's specificity is not absolute, as optochin-resistant S. pneumoniae strains—though uncommon—can produce false negatives, underscoring the need for orthogonal confirmation in equivocal results.

Test Procedure

The optochin susceptibility test is a disk diffusion assay used to differentiate from other alpha-hemolytic streptococci based on sensitivity to optochin (ethylhydrocupreine hydrochloride). The procedure follows standardized laboratory protocols to ensure reproducibility and accuracy in bacterial identification.

Materials

Essential materials include 6-mm filter paper disks impregnated with 5-10 μg of optochin, 5% sheep blood agar plates (typically prepared on a tryptic soy agar base supplemented with 5% defibrinated sheep blood for optimal growth and observation), a bacterial suspension adjusted to a 0.5 McFarland standard, sterile , and a millimeter or caliper for measuring inhibition zones. Incubation occurs in a 5% CO₂ atmosphere at 35-37°C.

Step-by-Step Protocol

  1. Prepare a bacterial suspension from pure colonies of the alpha-hemolytic isolate by emulsifying in saline or to match the 0.5 McFarland standard (approximately 1.5 × 10⁸ CFU/mL).
  2. Inoculate the suspension onto the surface of a 5% sheep by in multiple directions to achieve a confluent , allowing the plate to dry upright for 5-10 minutes.
  3. Using sterile , place the optochin-impregnated disk in the center of the inoculated area, applying gentle pressure to ensure contact with the agar; optionally, add a drop of sterile to the disk to enhance .
  4. Invert the plate and incubate at 35-37°C in an atmosphere containing 5% CO₂ for 18-24 hours.
  5. After incubation, examine the plate for a zone of inhibition around the disk and measure its diameter in millimeters, ignoring zones with satellite growth or hazy edges.

Interpretation

A clear zone of inhibition with a diameter of ≥14 mm indicates optochin sensitivity, consistent with S. pneumoniae. Zones <14 mm or absent zones suggest resistance or identification as non-pneumococcal streptococci, such as viridans group streptococci, warranting confirmatory tests like bile solubility. Borderline zones (e.g., 11-13 mm) may require repeat testing or alternative methods due to potential variability from media or incubation conditions.

Quality Control

Quality control strains must be included with each test batch to validate performance. Use S. pneumoniae ATCC 49619 as a sensitive control, which should produce a zone ≥14 mm, and a resistant strain such as Streptococcus mitis ATCC 49456 or NCTC 10712, which should show no zone or <6 mm. These controls confirm disk potency, media suitability, and incubation conditions.

Variations

In research settings, Etest strips impregnated with a gradient of optochin concentrations can determine the minimum inhibitory concentration (MIC) for more precise susceptibility assessment, particularly for strains with ambiguous disk diffusion results; the MIC is read where the ellipse of inhibition intersects the strip scale after similar inoculation and incubation. This method is not routine for clinical identification but aids in studying resistance mechanisms.

Mechanism of Action

Biochemical Inhibition

Optochin primarily inhibits the F0F1-ATP synthase complex embedded in the cytoplasmic membrane of sensitive Streptococcus pneumoniae strains, disrupting the enzyme's ability to harness the proton motive force for ATP synthesis. This inhibition occurs through specific binding to the proteolipid c subunit (encoded by atpC) within the F0 sector, which blocks proton translocation across the membrane and prevents the rotational mechanism necessary for ATP production in the F1 sector. The resulting disruption of the proton gradient leads to a rapid collapse of the , impairing energy-dependent cellular functions such as active nutrient transport, homeostasis, and in optochin-sensitive pneumococci. This metabolic arrest ultimately causes growth inhibition and in susceptible strains, as the bacterium relies heavily on for energy generation under aerobic conditions. At diagnostic concentrations of 5–10 μg, as used in standard disk diffusion tests, optochin exhibits selective toxicity toward S. pneumoniae without broadly impacting other gram-positive cocci, due to its targeted interaction with the pneumococcal . Biochemical assays on isolated pneumococcal membranes have demonstrated that optochin potently blocks activity in wild-type strains, with inhibition reduced over 100-fold in resistant mutants, confirming the enzyme as the primary site of action. Optochin shows no significant impact on eukaryotic cells at these low diagnostic doses, attributable to structural differences in the ATP synthase, particularly in the c subunit's transmembrane helices, which prevent effective binding in mitochondrial complexes.

Specificity to Pneumococcus

Optochin exhibits high specificity to Streptococcus pneumoniae due to distinct structural features in the pneumococcal ATP synthase that enable selective binding and inhibition, distinguishing it from closely related alpha-hemolytic streptococci in the viridans group. The F₀ portion of the H⁺-ATPase, particularly the c subunit encoded by the atpC gene, possesses a unique amino acid sequence in S. pneumoniae that forms a binding site for optochin, leading to potent inhibition of ATPase activity with a 100-fold greater sensitivity compared to resistant strains or species. In viridans streptococci such as Streptococcus oralis and Streptococcus mitis, sequence divergences in the homologous atpC and adjacent atpA genes result in a subunit composition that precludes effective optochin interaction, rendering their ATP synthases inherently resistant. This structural vulnerability is amplified by physiological differences, as S. pneumoniae shows greater reliance on the proton motive force (PMF) generated by its for critical functions, including cytoplasmic regulation and inorganic cation transport under acidic or stressful conditions common in the . S. pneumoniae depends almost exclusively on its F₀F₁-ATPase to maintain a PMF of approximately -130 to -150 mV, making optochin-induced disruption particularly lethal. In vitro comparative assays underscore this selectivity, with optochin demonstrating 99% sensitivity among clinical S. pneumoniae isolates—evidenced by inhibition zones of ≥14 mm—while susceptibility occurs in fewer than 2% of viridans group isolates, achieving 98% overall specificity for pneumococcal identification. These results highlight optochin's utility in differentiating S. pneumoniae from non-pneumococcal streptococci without significant . Evolutionarily, optochin's quinine-like structure capitalizes on membrane-embedded topological differences in the c subunit that emerged in S. pneumoniae as part of its adaptation to the human host, diverging from commensal viridans ancestors like S. oralis through accumulated changes in the atp . Rare exceptions include intrinsically resistant S. pneumoniae variants harboring natural polymorphisms in atpC (e.g., at codons 48-50) or atpA (e.g., at codon 206), which subtly alter the F₀ complex topology and reduce optochin affinity without requiring selective pressure.

Resistance

Mechanisms

Optochin resistance in primarily arises from point in the atpC or atpA genes, which encode the c and a subunits, respectively, of the F₀F₁ , altering the transmembrane region and thereby disrupting the for optochin. These , often occurring in codons such as 49 (e.g., Ala49Ser, Ala49Thr, Ala49Gly), 45 (e.g., Phe45Leu, Phe45Val), 47 (e.g., Gly47Val), and others like Met23Ile or Gly20Ala in atpC, or Trp206Cys in atpA, reduce the enzyme's sensitivity to the drug by changing the hydrophobicity and structure of the α-helices involved in proton translocation. Such genetic alterations are strictly chromosomal, with no reported instances of conferring this . Laboratory conditions, particularly frozen storage in containing 15% at -70°C, can induce optochin resistance by selecting for stress-induced subpopulations, potentially through spontaneous in atpC. In one study, 24.3% of 115 stored isolates developed resistance, characterized by altered and reversible upon in broth, highlighting how stresses the bacterial and favors resistant variants. In vitro selection experiments demonstrate stepwise development of resistance, where susceptible strains like D39 are exposed to optochin-containing media (e.g., 6 mg/L ), yielding spontaneous mutants at frequencies of 1.6 × 10⁻⁴ to 3.2 × 10⁻⁴, far higher than wild-type transformation rates. These mutants exhibit minimum inhibitory concentrations (MICs) elevated 4- to 64-fold over susceptible strains (typically 1-2 μg/mL for wild-type), reaching 8-64 μg/mL, with common mutations like Ala49Ser or Gly47Val mirroring those in clinical isolates. Passage through mouse models further generates additional variants, such as Leu26Met or Leu184Ser, underscoring the mutability of the under selective pressure.

Prevalence and Implications

The prevalence of optochin-resistant Streptococcus pneumoniae strains remains low globally, typically ranging from 1% to 5% among clinical and carriage isolates in most regions. For instance, in , approximately 2% of 1,973 pneumococcal strains isolated from nasopharyngeal carriers since 2001 exhibited optochin resistance. Similar rates, around 3.2%, were reported among invasive isolates recovered in in 2005. In , optochin resistance was detected in 0.68% of S. pneumoniae isolates from clinical samples. Overall, resistance does not exceed 5% in routine surveillance outside localized contexts. Trends in optochin resistance have shown a gradual increase since the , attributed to selective pressure from widespread use, which promotes the of resistant subpopulations within S. pneumoniae. This rise coincides with broader patterns in pneumococci, exacerbated by community and hospital exposure to agents like penicillin and . In the vaccine era following the introduction of pneumococcal conjugate vaccines, recent 2025 studies indicate the persistence of optochin-resistant clones, complicating post-vaccination . A February 2025 genomic study in analyzed whole-genome sequencing data from 10 pairs of optochin-susceptible and resistant S. pneumoniae isolates from invasive disease cases in the (2019–2020), revealing dual subpopulations within single patient samples and highlighting ongoing evolutionary adaptation. Key risk factors for optochin resistance include prior exposure to subinhibitory concentrations of antibiotics, such as penicillin, which may select for resistant variants during nasopharyngeal . High carriage rates in children attending day care centers and passive exposure to antibiotics in settings further contribute to transmission of resistant strains. Hospital environments also pose risks, as immunocompromised patients and those with recent hospitalizations are more likely to harbor or acquire resistant pneumococci. The diagnostic implications of optochin resistance are significant, as it can lead to false-negative results in the optochin susceptibility test, potentially misidentifying S. pneumoniae as other alpha-hemolytic streptococci and delaying appropriate management. To mitigate this, laboratories recommend confirmatory tests such as bile solubility assays, PCR targeting pneumococcal-specific genes, or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for accurate identification. These additional methods are essential in regions with rising resistance, ensuring reliable presumptive diagnosis without over-reliance on optochin alone. Clinically, optochin-resistant S. pneumoniae strains demonstrate comparable to susceptible counterparts, with no of increased invasiveness or direct association with treatment failure, as optochin is used solely for diagnostic purposes rather than . However, resistance complicates pneumococcal surveillance and outbreak detection, potentially underestimating if misidentification occurs. Among resistant isolates, susceptibility varies, with about 50% remaining fully susceptible to common agents and 21% exhibiting multidrug resistance, underscoring the need for routine susceptibility testing in affected cases.

References

  1. https://pubchem.ncbi.nlm.nih.gov/compound/Optochin
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC7346871/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC8041871/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC5376432/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC104639/
  6. https://microbenotes.com/optochin-susceptibility-test-principle-procedure-and-results/
  7. https://pubchem.ncbi.nlm.nih.gov/compound/Ethylhydrocupreine-hydrochloride
  8. https://microbiologyinfo.com/optochin-susceptibility-test-for-the-identification-of-streptococcus-pneumoniae/
  9. https://www.rcpath.org/asset/CE366F3F-25B9-490F-8C2CFB6728F24987/
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC2446823/
  11. https://academic.oup.com/cid/article-pdf/23/4/790/819118/23-4-790.pdf
  12. https://www.whatisbiotechnology.org/index.php/exhibitions/antimicrobial/index/evidence
  13. https://academic.oup.com/jid/article/179/Supplement_2/S338/2191188
  14. https://journals.asm.org/doi/10.1128/jcm.36.3.833-834.1998
  15. https://www.scirp.org/journal/paperinformation?paperid=18260
  16. https://pubmed.ncbi.nlm.nih.gov/14354032/
  17. https://journals.asm.org/doi/10.1128/jcm.02318-07
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC88350/
  19. https://pubmed.ncbi.nlm.nih.gov/11526182/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC2224255/
  21. https://pubmed.ncbi.nlm.nih.gov/11474432/
  22. https://www.simpios.eu/wp-content/uploads/2024/04/tp25_4_en_Optochina181203.pdf
  23. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2958.1994.tb01045.x
  24. https://journals.asm.org/doi/pdf/10.1128/jb.178.8.2455-2458.1996
  25. https://pubs.acs.org/doi/10.1021/acsinfecdis.8b00300
  26. https://www.sciencedirect.com/topics/medicine-and-dentistry/ethylhydrocupreine
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC98938/
  28. https://journals.asm.org/doi/10.1128/jcm.39.9.3373-3375.2001
  29. https://www.nature.com/articles/s41598-021-87071-8
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC3811620/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC2045260/
  32. https://www.sciencedirect.com/science/article/abs/pii/S0732889307000302
  33. https://pubmed.ncbi.nlm.nih.gov/17227208/
  34. https://file.scirp.org/Html/2-2260011_18260.htm
  35. https://journals.asm.org/doi/10.1128/jcm.01168-13
  36. https://stacks.cdc.gov/view/cdc/14315/cdc_14315_DS1.pdf
  37. https://academic.oup.com/cid/article-pdf/41/2/139/5948150/41-2-139.pdf
  38. https://academic.oup.com/jac/article/80/Supplement_4/iv72/8301265
  39. https://journals.asm.org/doi/10.1128/spectrum.01939-24
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC5921789/
  41. https://www.cdc.gov/pneumococcal/php/drug-resistance/index.html
  42. https://www.ijidonline.com/article/S1201-9712%2808%2900837-0/fulltext
Add your contribution
Related Hubs
User Avatar
No comments yet.